Terminated PHASE2 INTERVENTIONAL 4-arm NCT04914897

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)

A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Pleural Mesothelioma

Sponsor: Merck Sharp & Dohme LLC

Conditions Non-small Cell Lung Cancer Pleural Mesothelioma

Interventions Pembrolizumab THOR-707

Updated 24 times since 2021 Last updated: Sep 12, 2025 Started: Sep 23, 2021 Primary completion: Jul 18, 2023 Completion: Oct 17, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Early discontinuation based on strategic sponsor decision not driven by any safety concerns.

Other terminated trials from Merck Sharp & Dohme LLC

More terminations from Merck Sharp & Dohme LLC

Other Non-small Cell Lung Cancer trials with similar outcome

Browse all Non-small Cell Lung Cancer trials

This PHASE2 trial investigates Non-small Cell Lung Cancer and Pleural Mesothelioma and is currently terminated or withdrawn. Merck Sharp & Dohme LLC leads this study, which shows 24 recorded versions since 2021 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

24 versions recorded

Dec 2025 — Present [monthly]

Terminated PHASE2
Nov 2025 — Dec 2025 [monthly]

Terminated PHASE2
Sep 2025 — Nov 2025 [monthly]

Terminated PHASE2
Nov 2024 — Sep 2025 [monthly]

Terminated PHASE2

Status: Active Not Recruiting → Terminated
Sep 2024 — Nov 2024 [monthly]

Active Not Recruiting PHASE2

▶ Show 19 earlier versions

Aug 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Aug 2024 [monthly]

Active Not Recruiting PHASE2
Apr 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE2
Mar 2024 — Apr 2024 [monthly]

Active Not Recruiting PHASE2
Feb 2024 — Mar 2024 [monthly]

Active Not Recruiting PHASE2
Sep 2023 — Feb 2024 [monthly]

Active Not Recruiting PHASE2
Mar 2023 — Sep 2023 [monthly]

Active Not Recruiting PHASE2
Dec 2022 — Mar 2023 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE2
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE2
Jul 2022 — Sep 2022 [monthly]

Recruiting PHASE2
Jun 2022 — Jul 2022 [monthly]

Recruiting PHASE2
May 2022 — Jun 2022 [monthly]

Recruiting PHASE2
Mar 2022 — May 2022 [monthly]

Recruiting PHASE2
Feb 2022 — Mar 2022 [monthly]

Recruiting PHASE2
Dec 2021 — Feb 2022 [monthly]

Recruiting PHASE2
Nov 2021 — Dec 2021 [monthly]

Recruiting PHASE2
Oct 2021 — Nov 2021 [monthly]

Recruiting PHASE2
Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC
Sanofi

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aviano (PN), Italy , Barcelona, Spain , Bologna, Italy , Bordeaux, France , CABA, Argentina , Gdansk, Poland , Girona, Spain , Madrid, Spain , Milan, Italy , Olsztyn, Poland and 18 more locations